|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B 显示文摘 | Demakos EP Peterson BL | 2002 | J Clin Oncol2002，20，10： | 1 |
| 2 | Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes 显示文摘 | Silverman LR Fenaux P Mufti GJ | 2011 | Cancer2011，117，12： | 1 |
| 3 | Effects of azacitidine compared with conventional care regimens in elderly ( ≥ 75 years ) patients with higher-risk myelodysplastic syndromes显示文摘 | Seymour JF Fenaux P Silverman LR | 2010 | Crit Rev Oncol Hernatol2010，76，3： | 1 |
| 4 | Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes显示文摘 | Silverman LR Holland JF Weinberg RS | 1993 | Leukemia1993，71，： | 1 |
| 5 | Response rates in patients with acute myeloid leukemia,treated with azacytidine,using WHO and intenrational working group criteria for myelodysplastic syndrome显示文摘 | Silverman LR McKenzie DR Peterson BL | 2005 | Blood2005，106，： | 1 |
| 6 | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancer and leukemia group B显示文摘 | Silverman LR Demakos EP Peterson BL | 2002 | J Clin Oncol2002，20，： | 1 |
| 7 | Response rates in patients with acute myeloid leukemia, treated with azacytidine, using WHO and intenrational working group criteria for myelodysplastic syndrome 显示文摘 | Silverman LR McKenzie DR Peterson BL | 2005 | Blood2005，106，： | 1 |
| 8 | Further analysis of trials with azacitidine in patients with myelodysplastic syndrome:studies 8421,8921,and 9221 by the Cancer and Leukemia Group B显示文摘 | Silverman LR McKenzie DR Peterson BL | 2006 | J Clin Oncol2006，24，： | 1 |
| 9 | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B 显示文摘 | Silverman LR Demakos EP Peterson BL | 2002 | J Clin Oncol2002，20，： | 1 |
| 10 | Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421,8921, and 9221 by the Cancer and Leukemia Group B 显示文摘 | Silverman LR McKenzie DR Peterson BL | 2006 | J Clin Oncol2006，24，： | 1 |
| 11 | A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the new york cancer consortium显示文摘 | Silverman LR Verma A Odchimar-Reissig R | 2008 | Blood2008，112，11： | 1 |
| 12 | SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes显示文摘 | Giles FJ Stopeck AT Silverman LR | 2003 | Blood2003，102，3： | 1 |
| 13 | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancer and leukemia group B显示文摘 | Silverman LR | 2002 | J Clin Oncol2002，20，： | 1 |
| 14 | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancer and leukemia group B显示文摘 | Silverman LR Demakos EP Peterson BL | 2002 | J Clin Oncol2002，20，10： | 1 |
| 15 | Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B显示文摘 | Silverman LR Mckenzie DR Peterson BL | 2006 | J Clin Oncol2006，24，24： | 1 |
| 16 | Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes显示文摘 | Silverman LR Fenaux P Mufti G J | 2011 | Cancer2011，117，12： | 1 |
| 17 | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the cancer and leukemia group B显示文摘 | Silverman LR Dernakos EP Peterson BL | 2002 | J Clin Oncol2002，20，10： | 1 |
| 18 | Comparison of acellular dermal matrix and synthetic mesh for lateral chest wall reconstruction in a rabbit model 显示文摘 | Holton LR Chung T Silverman RP | 2007 | Plast Reconstr Surg2007，4，： | 1 |
| 19 | SU5416,a small molecule tyrosine kinase receptor inhibitor,has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes显示文摘 | GILES FJ STOPECK AT SILVERMAN LR | 2003 | Blood2003，102，3： | 1 |
| 20 | Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastie syndromes显示文摘 | Silverman LR Fenaux P Mufti G J | 2011 | Cancer2011，117，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员